ArticleScientific reports2025
MYC-mediated transcriptional control of splicing factors promotes RNA splicing in activated B lymphocytes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Germinal center B cells play a pivotal role in the generation of long-lived plasma cells and high-affinity antibodies. Although RNA splicing and alternative splicing are known to regulate germinal center B cell responses, the upstream mechanisms controlling these splicing events remain poorly understood. RNA sequencing analysis revealed significant upregulation of alternative splicing factors and core spliceosome genes in germinal center B cells. Genome-wide binding analyses using CUT&RUN and ChIP-seq confirmed that MAX and MYC physically bind to the promoters of these splicing regulators. High MYC expression in B cells markedly upregulated multiple splicing factors, whereas MAX knockout substantially suppressed their expression. Through splicing event profiling, we demonstrated that MYC promotes the excision of introns and alternative exons by upregulating splicing factor expression. Additionally, we identified E2F1 as another transcriptional regulator that occupies splicing factor promoters. Genetic ablation of E2F1 disrupted germinal center B cell and follicular helper T cell populations; however, its deletion in activated B cells had minimal effect on global spliceosome gene expression. These findings establish MYC as an upstream regulator that controls both splicing factor expression and splicing event alterations in activated B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.